EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00963248|
Recruitment Status : Completed
First Posted : August 21, 2009
Last Update Posted : April 13, 2015
In which stage of an EBV-infection is a selective reduction of immunosuppressive medication reasonable to minimize the risk for PTLD, without putting the transplant recipient at risk of acute rejection episodes due to under immunosuppression?
Aim of study:
Identification of patients at high-risk for PTLD.
|Condition or disease|
|Epstein-Barr Virus Infections|
|Study Type :||Observational|
|Actual Enrollment :||106 participants|
|Official Title:||Surveillance of EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients - a Multicenter Prospective Study|
|Study Start Date :||July 2003|
|Actual Primary Completion Date :||August 2010|
|Actual Study Completion Date :||August 2010|
- EB viral load, serology and EBV-specific T cell in pediatric (and adult) renal transplant recipients with or without clinical symptoms of EBV, PTLD etc. [ Time Frame: 9 years ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00963248
|Heidelberg, Germany, 69120|
|Principal Investigator:||Burkhard Toenshoff, MD, PhD||University Children's Hospital of Heidelberg|